Negar Hosseinkhani

Tabriz University of Medical Sciences — IR

Medicine · Health Sciences

11h-index479citations14works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(10), Immune Cell Function and Interaction(4), Immune cells in cancer(4), CAR-T cell therapy research(4), MicroRNA in disease regulation(3)

Publications14 total

Docetaxel treatment together with CTLA-4 knockdown enhances reduction of cell viability and amplifies apoptosis stimulation of MCF-7 breast cancer cells
Cytotechnology·2024Open Access
Dual silencing of tumor-intrinsic VISTA and CTLA-4 stimulates T-cell mediated immune responses and inhibits MCF7 breast cancer development
Gene·2023· 18 cited
Dual Silencing of Tumor-Intrinsic VISTA and CTLA-4 Stimulates T-Cell Mediated Immune Responses and Inhibits MCF7 Breast Cancer Development
SSRN Electronic Journal·2023· 3 citedOpen Access
A scoping review on the significance of programmed death-ligand 1-inhibiting microRNAs in non-small cell lung treatment: A single-cell RNA sequencing-based study
Frontiers in Medicine·2022· 16 citedOpen Access
The expression pattern of VISTA in the PBMCs of relapsing-remitting multiple sclerosis patients: A single-cell RNA sequencing-based study
Biomedicine & Pharmacotherapy·2022· 15 citedOpen Access
B7 immune checkpoint family members as putative therapeutics in autoimmune disease: An updated overview
International Journal of Rheumatic Diseases·2022· 8 cited
A Systematic Review and Meta-Analysis on the Significance of TIGIT in Solid Cancers: Dual TIGIT/PD-1 Blockade to Overcome Immune-Resistance in Solid Cancers
International Journal of Molecular Sciences·2021· 24 citedOpen Access
A scoping review on the potentiality of PD-L1-inhibiting microRNAs in treating colorectal cancer: Toward single-cell sequencing-guided biocompatible-based delivery
Biomedicine & Pharmacotherapy·2021· 28 citedOpen Access
A Systematic Review of the Tumor-Infiltrating CD8+ T-Cells/PD-L1 Axis in High-Grade Glial Tumors: Toward Personalized Immuno-Oncology
Frontiers in Immunology·2021· 22 citedOpen Access
The Prognostic Value of CD133 in Predicting the Relapse and Recurrence Pattern of High-Grade Gliomas on MRI: A Meta-Analysis
Frontiers in Oncology·2021· 17 citedOpen Access
A Systematic Review to Clarify the Prognostic Values of CD44 and CD44+CD24- Phenotype in Triple-Negative Breast Cancer Patients: Lessons Learned and The Road Ahead
Frontiers in Oncology·2021· 35 citedOpen Access
The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead
Frontiers in Immunology·2021· 66 citedOpen Access
Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?
International Journal of Molecular Sciences·2020· 99 citedOpen Access
Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials
International Journal of Molecular Sciences·2020· 128 citedOpen Access

Frequent Co-authors

Mahdi Abdoli Shadbad(10), Oronzo Brunetti(9), Nicola Silvestris(9), Afshin Derakhshani(8), Behzad Baradaran(8), Behzad Baradaran(6), Zahra Asadzadeh(6), Amir Baghbanzadeh(5), Ahad Mokhtarzadeh(5), Vito Racanelli(4), Noora Karim Ahangar(4), Nazila Alizadeh(4), Khalil Hajiasgharzadeh(3), Tohid Kazemi(3), Nima Hemmat(3), Elham Baghbani(3), Omid Kooshkaki(2), Hossein Safarpour(2), Antonella Argentiero(2), Parisa Lotfinejad(2)